Abstract 214P
Background
Small cell lung cancer (SCLC) is currently treated with a combination of chemotherapy and immunotherapy. Unfortunately, not all patients benefit from this regimen and few alternative therapies are available. Based on recent transcriptomic data defining an “inflamed” subtype of SCLC patients who benefit from immunotherapy, we hypothesised that innate immune activation and natural killer (NK) cells may provide an opportunity to evaluate immune-responsive patients.
Methods
SCLC patients receiving two cycles of chemo-immunotherapy were divided into best responders (BR) and non-responders (NR). NK cells from SCLC patients (n=10) were isolated from peripheral blood-collected PBMCs and subjected to RNA-seq and gene set enrichment analysis (GSEA). Isolated NK cells were in vitro treated with DNA-dependent protein Kinase (DNA-PK) inhibitor. RT-PCR, Seahorse assay and flow cytometry were performed to investigate immune checkpoint expression.
Results
GSEA analysis of RNAseq data on NK cells from BR patients of SCLC cohorts showed high levels of IFN-related pathways (IFN_GAMMA_RESPONSE NES=2.77; p<0.0001, IFN_ALPHA_RESPONSE NES=2.49; p<0.0001) and Influenza infection (NES=3.57; p<0.0001) enrichment in BR patients derived NK cells in comparison to NR patients. In addition, NK cells from BR patients showed enrichment in oxidative phosphorylation genes (NES=2.14; p<0.0001) as well as DNA repair pathway (NES=2.07; p<0.0001). ISMARA analysis revealed that BR patients-derived NK cells showed high Interferon regulatory factor 3 (IRF3)-binding motif (Pearson corr. coeff. = 0.76; p<0.0001) compared to the NR cohort. In vitro treatment of NK cells with DNA-PKi significantly increased multiple innate immunity cytosolic DNA/RNA sensors, namely cGAS-STING (p < 0.0001), MAVS (p < 0.0001) and IFI16 (p < 0.0001). Finally, metabolic analysis showed an increase in ATP production Rate and phenotypic characterization by flow cytometry showed an increase in ICOS (CD278) expression in DNA-PKi- treated NK cells.
Conclusions
Comprehensive transcriptomic analysis of SCLC-isolated NK cells revealed significant positive modulation of innate immune pathways, suggesting a potential role for DNA-PKi in metabolic and phenotypic remodelling.
Legal entity responsible for the study
The authors.
Funding
Associazione Italiana per la Ricerca sul Cancro (AIRC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract